Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 77K | 77K | 77K | 77K | 70K |
| Gross Profit | 77K | 70K | 72K | 77K | 70K |
| Operating Income | -1M | -1M | -1M | -1M | -1M |
| EBITDA | -1M | 56K | -1M | -1M | -2M |
| Net Income | -2M | -2M | -2M | -1M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0006
+0.00% today
Window Change
+200.00%
Window
Jul 23, 2025 → Jun 17, 2026
Coverage: 227 bars · Jul 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RegeneRx Biopharmaceuticals, Inc. (RGRX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 200.0% across the available one-year price window (Jul 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -7094.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -7094.2%, free cash flow +5.0% with operating margin -1826.4% and ROIC 1654.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RGRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGRX Max Drawdown
-99.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RGRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$69.7K
-9.2% YoY
FY Net Income
-$2.0M
-42.0% YoY
Free Cash Flow
-$888.3K
+21.9% YoY
Revenue Growth
+0.0%
EPS Growth
-7094.2%
Gross Margin
100.0%
Net Margin
-2249.8%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 77K | 77K | 77K | 77K | 70K |
| Gross Profit | 77K | 70K | 72K | 77K | 70K |
| Operating Income | -1M | -1M | -1M | -1M | -1M |
| EBITDA | -1M | 56K | -1M | -1M | -2M |
| Net Income | -2M | -2M | -2M | -1M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 291K | 1M | 428K | 640K | 237K |
| Total Assets | 382K | 1M | 552K | 712K | 281K |
| Total Liabilities | 4M | 4M | 3M | 3M | 2M |
| Shareholder Equity | -3M | -2M | -3M | -2M | -2M |
| Total Debt | 1M | 1M | 1M | 735K | 55K |
| Net Debt | 1M | -67K | 598K | 95K | -183K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
888K
+21.9% YoY
Capital Expenditures
0
Free Cash Flow
888K
+21.9% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-1826.4%
Net Margin
-2249.8%
ROE
60.9%
Debt / Equity
-0.42x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.